Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR
Links shared publicly online about this topic.
- 1,512total visits
Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR
View full resource at news-medical.net
Tags: HIV, AIDS, HIV Medication, STD, Drug, Children's Health, FDA, Sustiva
Most Recently Shared on December 22, 2009 at 5:24 pm By:
HIV/AIDS News: Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR: Mylan Inc. today... http://bit.ly/8Rmpkl
Also Shared By:
FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA
news-medical.net — “Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.” View full resource at news-medical.net
Most Recently Shared on January 20, 2011 at 2:21 pm By:
HIV/AIDS News: FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA: Mylan In... http://bit.ly/dXASt0
Matrix Laboratories receives tentative FDA approval for its NDA
news-medical.net — “Mylan Inc. today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 600 mg/300 mg/300 mg.” View full resource at news-medical.net
Most Recently Shared on September 16, 2009 at 7:06 pm By:
HIV/AIDS News: Matrix Laboratories receives tentative FDA approval for its NDA: Mylan Inc. today a.. http://bit.ly/3N4P3h
Advertisement
News-Medical.Net
@NewsMedical
Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR: Mylan Inc. today announced that... http://bit.ly/8Rmpkl
1 year ago...